These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 29790314)
1. Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma. Kulason KO; Schneider JR; Chakraborty S; Filippi CG; Pramanik B; Wong T; Fralin S; Tan K; Ray A; Alter RA; Ortiz R; Demopoulos A; Langer DJ; Boockvar JA J Exp Ther Oncol; 2018 May; 12(3):223-229. PubMed ID: 29790314 [TBL] [Abstract][Full Text] [Related]
2. Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study. Chakraborty S; Filippi CG; Wong T; Ray A; Fralin S; Tsiouris AJ; Praminick B; Demopoulos A; McCrea HJ; Bodhinayake I; Ortiz R; Langer DJ; Boockvar JA J Neurooncol; 2016 Jul; 128(3):405-15. PubMed ID: 26945581 [TBL] [Abstract][Full Text] [Related]
3. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial. McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP J Neurosurg Pediatr; 2021 Oct; 28(4):371-379. PubMed ID: 34359048 [TBL] [Abstract][Full Text] [Related]
4. Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response. Faltings L; Kulason KO; Patel NV; Wong T; Fralin S; Li M; Schneider JR; Filippi CG; Langer DJ; Ortiz R; Boockvar JA World Neurosurg; 2019 Nov; 131():234-241. PubMed ID: 31351210 [TBL] [Abstract][Full Text] [Related]
5. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490 [TBL] [Abstract][Full Text] [Related]
6. Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series. Shin BJ; Burkhardt JK; Riina HA; Boockvar JA Neurosurg Clin N Am; 2012 Apr; 23(2):323-9, ix-x. PubMed ID: 22440875 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509 [TBL] [Abstract][Full Text] [Related]
8. Guideline conformity to the Stupp regimen in patients with newly diagnosed glioblastoma multiforme in China. Wang Y; Zhang J; Li W; Jiang T; Qi S; Chen Z; Kang J; Huo L; Wang Y; Zhuge Q; Gao G; Wu Y; Feng H; Zhao G; Yang X; Zhao H; Wang Y; Yang H; Kang D; Su J; Li L; Jiang C; Li G; Qiu Y; Wang W; Wang H; Xu Z; Zhang L; Wang R Future Oncol; 2021 Nov; 17(33):4571-4582. PubMed ID: 34519220 [TBL] [Abstract][Full Text] [Related]
9. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182 [TBL] [Abstract][Full Text] [Related]
10. Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma. Chakraborty S; Filippi CG; Burkhardt JK; Fralin S; Ray A; Wong T; Ortiz R; Langer DJ; Boockvar JA J Exp Ther Oncol; 2016 Nov; 11(4):261-267. PubMed ID: 27849336 [TBL] [Abstract][Full Text] [Related]
11. Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma. Yoon SM; Kim JH; Kim SJ; Khang SK; Shin SS; Cho YH; Jwa E; Park JH; Ahn SD Tumori; 2013; 99(4):480-7. PubMed ID: 24326836 [TBL] [Abstract][Full Text] [Related]
12. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738 [TBL] [Abstract][Full Text] [Related]
13. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651 [TBL] [Abstract][Full Text] [Related]
14. Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial. Patel NV; Wong T; Fralin SR; Li M; McKeown A; Gruber D; D'Amico RS; Patsalides A; Tsiouris A; Stefanov DG; Flores O; Zlochower A; Filippi CG; Ortiz R; Langer DJ; Boockvar JA J Neurooncol; 2021 Nov; 155(2):117-124. PubMed ID: 34601657 [TBL] [Abstract][Full Text] [Related]
15. Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. Reddy K; Gaspar LE; Kavanagh BD; Chen C J Med Imaging Radiat Oncol; 2014 Dec; 58(6):714-21. PubMed ID: 24975917 [TBL] [Abstract][Full Text] [Related]
16. A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma. Beauchesne P; Quillien V; Faure G; Bernier V; Noel G; Quetin P; Gorlia T; Carnin C; Pedeux R Int J Cancer; 2016 Mar; 138(6):1538-44. PubMed ID: 26501997 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide. Younis SG; Khedr RA; El-Shorbagy SH J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634 [TBL] [Abstract][Full Text] [Related]
18. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. Riina HA; Fraser JF; Fralin S; Knopman J; Scheff RJ; Boockvar JA J Exp Ther Oncol; 2009; 8(2):145-50. PubMed ID: 20192120 [TBL] [Abstract][Full Text] [Related]
19. A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study. Illic R; Somma T; Savic D; Frio F; Milicevic M; Solari D; Nikitovic M; Lavrnic S; Raicevic S; Milosevic S; Cavallo LM; Cappabianca P; Grujicic D World Neurosurg; 2017 Aug; 104():581-588. PubMed ID: 28522381 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]